RT Journal Article
SR Electronic
T1 Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1403
OP 1409
DO 10.21873/anticanres.13255
VO 39
IS 3
A1 BYOUNG CHUL CHO
A1 TOMMASO DE PAS
A1 HARALABOS KALOFONOS
A1 QUN WANG
A1 RODRYG RAMLAU
A1 YING CHENG
A1 FABIANA VITIELLO
A1 TANEL LAISAAR
A1 ERIC VALLIÈRES
A1 BARTOSZ KUBISA
A1 SERGEY ORLOV
A1 KEUNCHIL PARK
A1 CHANNA DEBRUYNE
A1 JOHAN VANSTEENKISTE
YR 2019
UL http://ar.iiarjournals.org/content/39/3/1403.abstract
AB Background/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.